Braveheart Bio, a California-based biotech company focused on cardiovascular treatments, launched its IPO on Thursday, raising an impressive $382.5 million by offering 21.2 million shares at $18 each on the Nasdaq under the ticker “BRVE.” The funds will support the development of its lead asset, BHB-1893, an innovative oral therapy aimed at treating hypertrophic cardiomyopathy (HCM) by inhibiting cardiac myosin. Braveheart aims to compete with established drugs like Bristol Myers Squibb’s Camzyos in this market, pushing BHB-1893 through late-stage testing. This IPO is part of a broader trend, as 21 biotechs have gone public this year, taking advantage of a more favorable market.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/business/braveheart-pumps-more-life-into-biotech-ipo-market-with-382m-expected-debut
